Burden of hereditary transthyretin amyloidosis on quality of life

Aaron Yarlas, Morie A. Gertz, Noel Dasgupta, Laura Obici, Michael Pollock, Elizabeth J. Ackermann, Andrew Lovley, Asia Sikora Kessler, Pankaj A. Patel, Michelle K. White, Spencer D. Guthrie

Research output: Contribution to journalArticle

Abstract

Introduction: Hereditary transthyretin (hATTR) amyloidosis is a progressive, degenerative disease, with peripheral neuropathy, cardiomyopathy, and other clinical manifestations. In this study we examine the impact of hATTR amyloidosis on quality of life (QOL). Methods: Neuropathy-specific QOL, measured with the Norfolk QOL-Diabetic Neuropathy questionnaire, was compared between patients with hATTR amyloidosis and patients with type 2 diabetes, whereas generic QOL, measured with the 36-item Short Form Health Survey version 2 (SF-36v2), was compared between patients with hATTR amyloidosis, the general population, and patients with chronic diseases. Results: Neuropathy-specific QOL for patients with hATTR amyloidosis was nearly equivalent to that of patients with type 2 diabetes with diabetic neuropathy accompanied by a history of ulceration, gangrene, or amputation. Generic QOL was worse than that seen in the general population, with physical functioning worse than that for patients with multiple sclerosis and congestive heart failure. Discussion: Patients with hATTR amyloidosis show significant burden on QOL, particularly in physical functioning. Muscle Nerve, 2019.

Original languageEnglish (US)
JournalMuscle and Nerve
DOIs
StatePublished - Jan 1 2019

Fingerprint

Familial Amyloidosis
Quality of Life
Diabetic Neuropathies
Type 2 Diabetes Mellitus
Gangrene
Amyloidosis, Hereditary, Transthyretin-Related
Peripheral Nervous System Diseases
Health Surveys
Cardiomyopathies
Amputation
Population
Multiple Sclerosis
Chronic Disease
Heart Failure
Muscles

Keywords

  • ATTR amyloidosis
  • burden
  • polyneuropathy
  • quality of life
  • transthyretin amyloidosis

ASJC Scopus subject areas

  • Physiology
  • Clinical Neurology
  • Cellular and Molecular Neuroscience
  • Physiology (medical)

Cite this

Yarlas, A., Gertz, M. A., Dasgupta, N., Obici, L., Pollock, M., Ackermann, E. J., ... Guthrie, S. D. (2019). Burden of hereditary transthyretin amyloidosis on quality of life. Muscle and Nerve. https://doi.org/10.1002/mus.26515

Burden of hereditary transthyretin amyloidosis on quality of life. / Yarlas, Aaron; Gertz, Morie A.; Dasgupta, Noel; Obici, Laura; Pollock, Michael; Ackermann, Elizabeth J.; Lovley, Andrew; Kessler, Asia Sikora; Patel, Pankaj A.; White, Michelle K.; Guthrie, Spencer D.

In: Muscle and Nerve, 01.01.2019.

Research output: Contribution to journalArticle

Yarlas, A, Gertz, MA, Dasgupta, N, Obici, L, Pollock, M, Ackermann, EJ, Lovley, A, Kessler, AS, Patel, PA, White, MK & Guthrie, SD 2019, 'Burden of hereditary transthyretin amyloidosis on quality of life', Muscle and Nerve. https://doi.org/10.1002/mus.26515
Yarlas, Aaron ; Gertz, Morie A. ; Dasgupta, Noel ; Obici, Laura ; Pollock, Michael ; Ackermann, Elizabeth J. ; Lovley, Andrew ; Kessler, Asia Sikora ; Patel, Pankaj A. ; White, Michelle K. ; Guthrie, Spencer D. / Burden of hereditary transthyretin amyloidosis on quality of life. In: Muscle and Nerve. 2019.
@article{543501096d5847b39b8a0734e029b576,
title = "Burden of hereditary transthyretin amyloidosis on quality of life",
abstract = "Introduction: Hereditary transthyretin (hATTR) amyloidosis is a progressive, degenerative disease, with peripheral neuropathy, cardiomyopathy, and other clinical manifestations. In this study we examine the impact of hATTR amyloidosis on quality of life (QOL). Methods: Neuropathy-specific QOL, measured with the Norfolk QOL-Diabetic Neuropathy questionnaire, was compared between patients with hATTR amyloidosis and patients with type 2 diabetes, whereas generic QOL, measured with the 36-item Short Form Health Survey version 2 (SF-36v2), was compared between patients with hATTR amyloidosis, the general population, and patients with chronic diseases. Results: Neuropathy-specific QOL for patients with hATTR amyloidosis was nearly equivalent to that of patients with type 2 diabetes with diabetic neuropathy accompanied by a history of ulceration, gangrene, or amputation. Generic QOL was worse than that seen in the general population, with physical functioning worse than that for patients with multiple sclerosis and congestive heart failure. Discussion: Patients with hATTR amyloidosis show significant burden on QOL, particularly in physical functioning. Muscle Nerve, 2019.",
keywords = "ATTR amyloidosis, burden, polyneuropathy, quality of life, transthyretin amyloidosis",
author = "Aaron Yarlas and Gertz, {Morie A.} and Noel Dasgupta and Laura Obici and Michael Pollock and Ackermann, {Elizabeth J.} and Andrew Lovley and Kessler, {Asia Sikora} and Patel, {Pankaj A.} and White, {Michelle K.} and Guthrie, {Spencer D.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/mus.26515",
language = "English (US)",
journal = "Muscle and Nerve",
issn = "0148-639X",
publisher = "John Wiley and Sons Inc.",

}

TY - JOUR

T1 - Burden of hereditary transthyretin amyloidosis on quality of life

AU - Yarlas, Aaron

AU - Gertz, Morie A.

AU - Dasgupta, Noel

AU - Obici, Laura

AU - Pollock, Michael

AU - Ackermann, Elizabeth J.

AU - Lovley, Andrew

AU - Kessler, Asia Sikora

AU - Patel, Pankaj A.

AU - White, Michelle K.

AU - Guthrie, Spencer D.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Introduction: Hereditary transthyretin (hATTR) amyloidosis is a progressive, degenerative disease, with peripheral neuropathy, cardiomyopathy, and other clinical manifestations. In this study we examine the impact of hATTR amyloidosis on quality of life (QOL). Methods: Neuropathy-specific QOL, measured with the Norfolk QOL-Diabetic Neuropathy questionnaire, was compared between patients with hATTR amyloidosis and patients with type 2 diabetes, whereas generic QOL, measured with the 36-item Short Form Health Survey version 2 (SF-36v2), was compared between patients with hATTR amyloidosis, the general population, and patients with chronic diseases. Results: Neuropathy-specific QOL for patients with hATTR amyloidosis was nearly equivalent to that of patients with type 2 diabetes with diabetic neuropathy accompanied by a history of ulceration, gangrene, or amputation. Generic QOL was worse than that seen in the general population, with physical functioning worse than that for patients with multiple sclerosis and congestive heart failure. Discussion: Patients with hATTR amyloidosis show significant burden on QOL, particularly in physical functioning. Muscle Nerve, 2019.

AB - Introduction: Hereditary transthyretin (hATTR) amyloidosis is a progressive, degenerative disease, with peripheral neuropathy, cardiomyopathy, and other clinical manifestations. In this study we examine the impact of hATTR amyloidosis on quality of life (QOL). Methods: Neuropathy-specific QOL, measured with the Norfolk QOL-Diabetic Neuropathy questionnaire, was compared between patients with hATTR amyloidosis and patients with type 2 diabetes, whereas generic QOL, measured with the 36-item Short Form Health Survey version 2 (SF-36v2), was compared between patients with hATTR amyloidosis, the general population, and patients with chronic diseases. Results: Neuropathy-specific QOL for patients with hATTR amyloidosis was nearly equivalent to that of patients with type 2 diabetes with diabetic neuropathy accompanied by a history of ulceration, gangrene, or amputation. Generic QOL was worse than that seen in the general population, with physical functioning worse than that for patients with multiple sclerosis and congestive heart failure. Discussion: Patients with hATTR amyloidosis show significant burden on QOL, particularly in physical functioning. Muscle Nerve, 2019.

KW - ATTR amyloidosis

KW - burden

KW - polyneuropathy

KW - quality of life

KW - transthyretin amyloidosis

UR - http://www.scopus.com/inward/record.url?scp=85067412623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067412623&partnerID=8YFLogxK

U2 - 10.1002/mus.26515

DO - 10.1002/mus.26515

M3 - Article

C2 - 31093980

AN - SCOPUS:85067412623

JO - Muscle and Nerve

JF - Muscle and Nerve

SN - 0148-639X

ER -